These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1762 related articles for article (PubMed ID: 34603316)
21. Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. Duchnowska R; Pęksa R; Radecka B; Mandat T; Trojanowski T; Jarosz B; Czartoryska-Arłukowicz B; Olszewski WP; Och W; Kalinka-Warzocha E; Kozłowski W; Kowalczyk A; Loi S; Biernat W; Jassem J; Breast Cancer Res; 2016 Apr; 18(1):43. PubMed ID: 27117582 [TBL] [Abstract][Full Text] [Related]
22. GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors. Fu Y; Liu CJ; Kobayashi DK; Johanns TM; Bowman-Kirigin JA; Schaettler MO; Mao DD; Bender D; Kelley DG; Uppaluri R; Bi WL; Dunn IF; Tao Y; Luo J; Kim AH; Dunn GP Sci Rep; 2020 Jun; 10(1):9027. PubMed ID: 32493985 [TBL] [Abstract][Full Text] [Related]
23. Glial TIM-3 Modulates Immune Responses in the Brain Tumor Microenvironment. Kim HS; Chang CY; Yoon HJ; Kim KS; Koh HS; Kim SS; Lee SJ; Kane LP; Park EJ Cancer Res; 2020 May; 80(9):1833-1845. PubMed ID: 32094297 [TBL] [Abstract][Full Text] [Related]
24. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer. Lyu X; Wang P; Qiao Q; Jiang Y BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019 [TBL] [Abstract][Full Text] [Related]
25. Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8 Eissa IR; Mukoyama N; Abdelmoneim M; Naoe Y; Matsumura S; Bustos-Villalobos I; Ichinose T; Miyajima N; Morimoto D; Tanaka M; Fujimoto Y; Sone M; Kodera Y; Kasuya H Int J Cancer; 2021 Jul; 149(1):214-227. PubMed ID: 33687756 [TBL] [Abstract][Full Text] [Related]
26. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas. Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695 [TBL] [Abstract][Full Text] [Related]
27. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer. Huang K; Hu M; Chen J; Wei J; Qin J; Lin S; Du H Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068143 [TBL] [Abstract][Full Text] [Related]
28. CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors. Deng B; Park JH; Ren L; Yew PY; Kiyotani K; Antic T; O'Connor K; O'Donnell PH; Nakamura Y Cancer Rep (Hoboken); 2018 Jun; 1(1):e1002. PubMed ID: 32729250 [TBL] [Abstract][Full Text] [Related]
29. Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model. Lee EJ; Kim JH; Kim TI; Kim YJ; Pak ME; Jeon CH; Park YJ; Li W; Kim YS; Choi JG; Chung HS Front Immunol; 2021; 12():737076. PubMed ID: 34659228 [TBL] [Abstract][Full Text] [Related]
30. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis. Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325 [TBL] [Abstract][Full Text] [Related]
31. Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. Aslan K; Turco V; Blobner J; Sonner JK; Liuzzi AR; Núñez NG; De Feo D; Kickingereder P; Fischer M; Green E; Sadik A; Friedrich M; Sanghvi K; Kilian M; Cichon F; Wolf L; Jähne K; von Landenberg A; Bunse L; Sahm F; Schrimpf D; Meyer J; Alexander A; Brugnara G; Röth R; Pfleiderer K; Niesler B; von Deimling A; Opitz C; Breckwoldt MO; Heiland S; Bendszus M; Wick W; Becher B; Platten M Nat Commun; 2020 Feb; 11(1):931. PubMed ID: 32071302 [TBL] [Abstract][Full Text] [Related]
32. A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer. Flores-Martín JF; Perea F; Exposito-Ruiz M; Carretero FJ; Rodriguez T; Villamediana M; Ruiz-Cabello F; Garrido F; Cózar-Olmo JM; Aptsiauri N Ann Surg Oncol; 2019 Aug; 26(8):2631-2639. PubMed ID: 31011905 [TBL] [Abstract][Full Text] [Related]
33. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470 [TBL] [Abstract][Full Text] [Related]
34. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome. Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034 [TBL] [Abstract][Full Text] [Related]
35. Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression. Sudoyo AW; Kurniawan AN; Kusumo GD; Putra TP; Rexana FA; Yunus M; Budiyati AD; Kurniawan D; Utama A; Utomo AR Asian Pac J Cancer Prev; 2019 Nov; 20(11):3421-3427. PubMed ID: 31759368 [TBL] [Abstract][Full Text] [Related]
36. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy. Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323 [TBL] [Abstract][Full Text] [Related]
37. Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination. De Guillebon E; Dardenne A; Saldmann A; Séguier S; Tran T; Paolini L; Lebbe C; Tartour E Int J Cancer; 2020 Sep; 147(6):1509-1518. PubMed ID: 31997345 [TBL] [Abstract][Full Text] [Related]
38. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345 [TBL] [Abstract][Full Text] [Related]
39. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC). Farrag MS; Abdelwahab K; Farrag NS; Elrefaie WE; Emarah Z J Egypt Natl Canc Inst; 2021 Jul; 33(1):16. PubMed ID: 34241710 [TBL] [Abstract][Full Text] [Related]
40. Development and validation of a PD-L1/PD-1/CD8 axis-based classifier to predict cancer survival of upper tract urothelial carcinoma after radical nephroureterectomy. Chen J; Zhong W; Yang M; Hou W; Wang X; Xia K; Yu H; Yang M; Zhou B; Wang B; Huang J; Lin T Cancer Immunol Immunother; 2021 Sep; 70(9):2657-2668. PubMed ID: 33606065 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]